Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Signal Transduction in NAFLD
2013-003791-12Phase 2Completed
- Sponsor
- University of Helsinki
- Start
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of human insulin in metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM), obesity and 1 more (2 cohorts), sponsored by University of Helsinki. Started Nov 2013; status: completed.
02
Drugs
human insulin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)obesityhypertension (HTN)
Beyond the preview
Go deeper on 2013-003791-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003791-12.